Diligence memo · auto-generated · as of July 2, 2026
Benchling, Inc.
Benchling, Inc. looks fair against its niche peers and is dormant on financing cadence.
Businessfiled
Benchling, Inc. operates in Biotech, based in SAN FRANCISCO, CA, USA. Unlocking the power of biotech with modern software for modern science
Sub-sector tags: B2B, Biotech, SaaS, biotech.
Capital & rounds (filed)filed
Benchling, Inc. has raised $7.0M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $7.0M on 2016-04-18.
Most recent recorded round closed around 2016-04-18.
Valuation (modeled)modeled
Provath models Benchling, Inc. at approximately $253M (range $7.6M–$1.4B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.11× the median modeled value of Series A Biotech companies in 2016–2018 (8 peers) — value vs value, same stage and era. Within the normal band (111% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 10.2 yr ago; this sector typically re-raises about every 11 months.
Only one round on record and long silent — often defunct, acquired, or gone quiet.
Comparablesmixed
Capital scale ranks ahead of 82% of Biotech peers (233 compared).
Modeled value ranks above 95% of those peers.
Closest niche peers: Montlake Bioscience Inc., Impact Genomics, Inc., Transplant Genomics Inc., Franklin BioScience - Penn LLC, Element Genomics, Inc..
Peoplefiled
3 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.